指南与共识浆细胞疾病

多发性骨髓瘤治疗:ASCO动态指南2026.1.3版

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3.
指南 / 共识 · J Clin Oncol · 2026-09-30

本指南为ASCO多发性骨髓瘤动态指南2026.1.3版,由常设专家组基于持续系统文献综述定期更新推荐。指南旨在随证据快速演变调整临床实践,不替代医生独立判断,具体推荐条款见正文框。

要点

  • ASCO动态指南由常设专家组持续系统综述文献并定期更新。
  • 本版为2026.1.3版,推荐条款见正文框,需结合患者个体情况应用。
  • 指南不替代治疗医生的独立专业判断。

核心结论

  • ASCO多发性骨髓瘤动态指南2026.1.3版基于持续系统文献综述定期更新治疗推荐。

研究设计与样本

  • 由常设专家组按ASCO指南方法学手册持续系统综述健康文献并定期更新。

临床怎么用

  • 临床应用于多发性骨髓瘤治疗决策时参考本动态指南推荐,并结合患者个体差异。

局限性

  • 动态指南不替代治疗医生的独立专业判断,也不考虑患者个体差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Banerjee R, Messersmith H, Ebraheem M, et al. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3. J Clin Oncol. 2026. PMID: 42814948. doi:10.1200/JCO-26-02399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。